Anistreplase - Wikipedia
Anistreplase is a thrombolytic drug. It is also known as anisoylated plasminogen streptokinase activator complex (APSAC). As a ... Anistreplase is used to treat blood clots in emergency situations such as myocardial infarction. Early treatment gives better ... Anistreplase is a complex of purified human plasminogen and bacterial streptokinase that has been acylated to protect the ... Grampion Region Early Anistreplase Trial (GREAT)". J Epidemiol Community Health. 47 (5): 377-381. doi:10.1136/jech.47.5.377. ...
Thrombolytic Therapy: Background, Thrombolytic Agents, Thrombolytic Therapy for Acute Myocardial Infarction
APSAC (anistreplase) is a complex of streptokinase and plasminogen that does not require free circulating plasminogen to be ... Like streptokinase, anistreplase does not distinguish between fibrin-bound and circulating plasminogen; consequently, it too ... The adult dose of APSAC (anistreplase) for AMI is 30 U given IV over 2-5 minutes. ...
Thrombolytic Therapy: Background, Thrombolytic Agents, Thrombolytic Therapy for Acute Myocardial Infarction
APSAC (anistreplase) is a complex of streptokinase and plasminogen that does not require free circulating plasminogen to be ... Like streptokinase, anistreplase does not distinguish between fibrin-bound and circulating plasminogen; consequently, it too ... The adult dose of APSAC (anistreplase) for AMI is 30 U given IV over 2-5 minutes. ...
Heparin (Intravenous Route, Subcutaneous Route) Before Using - Mayo Clinic
Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are receiving this medicine, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.. Using this medicine with any of the following medicines is not recommended. Your doctor may decide not to treat you with this medication or change some of the other medicines you take.. ...
Does thrombolysis in myocardial infarction (TIMI) perfusion grade 2 represent a mostly patent artery or a mostly occluded...
... indexes of myocardial infarction in 359 patients treated within 4 h with anistreplase (APSAC) or streptokinase. Serum enzymes ...
Akorn Inc Product News and Research
| CureHunter
Astellas Pharma Us Inc Product News and Research
| CureHunter
Citrate
plasminogen activators (Alteplase/Reteplase/Tenecteplase, Streptokinase, Urokinase/Saruplase, Anistreplase) • other serine ...
Cardiac rehabilitation: socially deprived patients are less likely to attend but patients ineligible for thrombolysis are less...
1995) Comparison of mortality from acute myocardial infarction in patients receiving anistreplase with those not receiving ...
Betaxolol Hydrochloride|N0000004400
A-化学物质数据库
Antithrombotic Agents - LiverTox - NCBI Bookshelf
Biologics - Laboratories - Office of NIH History and Stetten Museum
RePub, Erasmus University Repository:
Trombolytische therapie van het acute hartinfarct
0 (Fibrinolytic Agents), 81669-57-0 (Anistreplase), 9001-91-6 (Plasminogen), Acute Disease, Anistreplase, Costs and Cost ...
Retavase®
Reteplase, recombinant
... anistreplase, streptokinase and urokinase in a canine model of coronary artery thrombosis. JACC. 1992;19:433-440. ...
National Ambulatory Medical Care Survey, 1994
Plasminogen activator inhibitor 1 | DrugBank Online
Fibrinogen human: Uses, Interactions, Mechanism of Action | DrugBank Online
MeSH Browser
Anistreplase Preferred Term Term UI T048404. Date01/01/1999. LexicalTag NON. ThesaurusID ... Anistreplase Preferred Concept UI. M0024829. Registry Number. 81669-57-0. Scope Note. An acylated inactive complex of ... Anistreplase. Tree Number(s). D08.811.277.656.300.760.635.075. D08.811.277.656.300.775.075. D08.811.277.656.959.350.635.075. ... Anistreplase. Previous Indexing. Fibrinolytic Agents (1966-1990). Plasminogen (1966-1990). Streptokinase (1966-1990). Public ...
MeSH Browser
Anistreplase Preferred Term Term UI T048404. Date01/01/1999. LexicalTag NON. ThesaurusID ... Anistreplase Preferred Concept UI. M0024829. Registry Number. 81669-57-0. Scope Note. An acylated inactive complex of ... Anistreplase. Tree Number(s). D08.811.277.656.300.760.635.075. D08.811.277.656.300.775.075. D08.811.277.656.959.350.635.075. ... Anistreplase. Previous Indexing. Fibrinolytic Agents (1966-1990). Plasminogen (1966-1990). Streptokinase (1966-1990). Public ...
Drugs for Acute Coronary Syndromes - Cardiovascular Disorders - MSD Manual Professional Edition
Anistreplase, related to streptokinase, is similarly allergenic and slightly more expensive but can be given as a single bolus ... Because of the possibility of allergic reactions, patients who previously received streptokinase or anistreplase are not given ... Tenecteplase (TNK), alteplase (rTPA), reteplase (rPA), streptokinase, and anistreplase (anisoylated plasminogen activator ... by active bleeding or planned use of streptokinase or anistreplase). Choice of agent is somewhat involved. ...
Code System Concept
Edoxaban - Wikipedia
In human, 15-150 mg oral doses of edoxaban reach their maximum concentrations in blood 1-2 hours after ingestion. With 60 mg doses of isotope labeled edoxaban, 97% of the total radiation was detected after oral administration, with 62% from feces and 35% from urine. 49% of the total radiation from the feces and 24% from the urine were from edoxaban, the rest from its metabolites.[4] Metabolism occurs mostly via CES1, CYP3A4, CYP3A5 and enzymatic hydrolysis. CES1 oxidizes the tertiary amide carbonyl carbons of edoxabans to carboxylic acid groups. CYP3A4 and CYP3A5 oxidize edoxabans via hydroxylation or demethylation. In hydrolysis, 2-amino-5-chloropyridine moiety of edoxaban is removed. Glucuronidation occurs to a lesser extent via glucuronosyltransferases.[4] ...
DeCS
Anistreplase - Preferred Concept UI. M0024829. Scope note. An acylated inactive complex of streptokinase and human lysine- ... Anistreplase Entry term(s):. APSAC. Anisoylated Plasminogen-Streptokinase Activator Complex. BRL 26921. BRL-26921. BRL26921. ...
Thrombolytic Therapy: Background, Thrombolytic Agents, Thrombolytic Therapy for Acute Myocardial Infarction
APSAC (anistreplase) is a complex of streptokinase and plasminogen that does not require free circulating plasminogen to be ... Like streptokinase, anistreplase does not distinguish between fibrin-bound and circulating plasminogen; consequently, it too ... The adult dose of APSAC (anistreplase) for AMI is 30 U given IV over 2-5 minutes. ...
PLG - Therapeutic Proteins
How long should one carry the streptokinase warning card - lookformedical.com
When my husband was given Streptokinase in 1995 after a myocardial infarction, he was also given a card ... again. How long must he carry this card?
E0000163|Adriamycin|doxorubicin
Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial...
ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs ...